

# PSOGI International Symposium on Advanced Ovarian Cancer

# **Faculty**

J. Spiliotis
P. Sugarbaker

Under the Auspices of



Causes, Symptoms and Treatments
Multidisciplinary Approach

April 11<sup>th</sup>-13<sup>th</sup> 2019

Eugenides Foundation Athens, Greece



#### Welcome Address

Dear friends and colleagues,

It is a great pleasure for us to announce the organization of the **PSOGI International Symposium on Advanced Ovarian Cancer** which will be held in **Athens, Greece** on **April 11<sup>th</sup>-13<sup>th</sup>, 2019**.

Ovarian cancer remains the most lethal gynecological cancer worldwide. The cover stone of the management is extensive meticulous surgery and sustaining chemotherapy, on the other hand in the first three years after initial treatment 50-40% of the cases are recurrent do to chemoresistance, tumor biology and residual disease from inappropriate operation.

The PSOGI Symposium is a highly specialized symposium that promises a stimulating, multi-disciplinary program aimed at providing the latest ideas and information on management of health of patients suffering with ovarian cancer.

The scientific program of the PSOGI Symposium will be a stimulating combination of cutting edge scientific knowledge and practical advice. Eight sessions are planned covering diagnosis and pretreatment staging through follow-up. Evidence regarding cytoreductive surgery and perioperative chemotherapy will be presented and/or debated. After each session, audience participation will occur through voting on the proper answers to pertinent questions regarding best recommendations for patient management. A final draft concerning conclusions on diagnosis and treatment will be produced. Audience participation will be a key ingredient to the success of this event.

PSOGI Symposium is aimed at surgeons, gynecologist - oncologists, medical oncologists, clinicians, nurses, researchers, and allied health professionals.

The Symposium will feature the most distinguished and brightest experts from around the world, who will share their compelling analysis and valuable insights. Commentaries on rendered reports on several diagnostic and frequently controversial issues will be presented, in order to generate a fruitful discussion among the participants.

Our intention at the Symposium is to create an interactive symposium that will provide a forum for the exchange of ideas and experiences through a rigorous study, to spread and help the delegates to learn innovative care models, update methodologies and to assess the resulting outcomes from around the world. It will also create an opportunity to examine how fruitful collaborations can be struck between partners at local, national and international levels and to build systems that seamlessly provide care for the whole community, including people with complex care needs. The symposium will facilitate both scientific and human exchange.

We are looking forward to welcoming you to Athens!!!

Symposium Chairmen

#### Spiliotis J.

Surgical Oncologist,
Director and Chairman of the Peritoneal
Surface Malignancy Unit, European
Interbalkan Medical Center Thessaloniki,
Athens Medical Center, Athens, Greece

#### Sugarbaker P.

Medical Director, Center for Gastrointestinal Malignancies, Chief, Program in Peritoneal Surface Oncology, MedStar Washington Hospital Center, Washington, DC



# Symposium Chairmen

Spiliotis J. (Greece) Sugarbaker P. (USA)

# Organizing Committee

#### Spiliotis J.

Classe J.M. Deraco M. Kecmanovic D.

Kopanakis N.

## Scientific Committee

#### Sugarbaker P.

Kalogiannidis J. Lo Dico R. Sammartino P. Sioulas V.

# Local Advisory Committee

Akrivos N. Ferfelis M. Lianos F. Matheos D. Andreadis Ch. Floros Th. Aravantinos G. Georgoulias V. Metaxas Th. Baka S. lavazzo Ch. Nikolaou M. Barbounis V. Kalles V. Raptis A. Boutis A. Sioulas V. Kalogiannidis I. Christofylakis Ch. Stamou K. Karamouzis M. Christopoulou A. Katirtzoglou N. Strimpakos A. Efstathiou E. Kontovinis L. Tentes A.-A. Emmanouilides Ch. Kopanakis N. Varthalitis J. Farmakis D. Kyriazanos J. Vorgias G.

Lazarakis A.

Fassas Ath.

# International Advisory Committee

Akrivos N. (Greece)
Ansaloni L. (Italy)
Bakrin N. (France)
Bereder J.M. (France)
Canbay E. (Turkey)
Cellen W. (Belgium)
Classe J.M. (France)
Deraco M. (Italy)

Emmanouilides Ch. (Greece)

Eveno C. (France) Fagotti A. (Italy) Fotopoulou Ch. (UK) Gladieff L. (France)
Goere D. (France)
Hilaris G. (Greece)
Kecmanovic D. (Serbia)
Kitayama J. (Japan)
Kyriazanos J. (Greece)

Li Y. (China)

Lo Dico R. (France) Morris D. (Australia)

Nissan A. (Israel) Panoskaltsis T. (Greece)

Fotopoulou Ch. (UK)

Gladieff L. (France)

Papakonstantinou K. (Greece)

Quadros C. (Brazil)
Quenet F. (France)
Sammartino P. (Italy)
Sgarbura O. (France)
Spiliotis J. (Greece)
Stamou K. (Greece)
Sugarbaker P. (USA)
Teo M. (Singapore)

Verwaal V. (Denmark) Yonemura Y. (Japan)

Vaira M. (Italy)

# International Steering Committee

Afsar B. (Turkey)
Ansaloni L. (Italy)
Bartlett D. (USA)
Bereder J.M. (France)
Bibeau F. (France)
Billard V. (France)
Canbay E. (Turkey)
Ceelen W. (Belgium)
Chive L. (Spain)
Classe J.M. (France)
Deraco M. (Italy)
Du Bois A. (Germany)

Eveno C. (France)

Fagotti A. (Italy)

Freyer G. (France)

Glehen M. (France)
Goere D. (France)
Kecmanovic D. (Serbia)
Kitayama J. (Japan)
Koole S. (Netherlands)
Li Y. (China)
Lo Dico R. (France)
Moran B. (UK)
Moreno S.G. (Spain)
Morris D. (Australia)
Nissan A. (Israel)
Passot G. (France)
Piso P. (Germany)

Pocard M. (France)
Quadros C. (Brazil)
Quenet F. (France)
Rau B. (Germany)
Rousset P. (France)
Sammartino P. (Italy)
Sgarbura O. (France)
Spiliotis J. (Greece)
Sugarbaker P. (USA)
Topgul K. (Turkey)
Vergote I. (Belgium)
Verwaal V. (Denmark)
Yonemura Y. (Japan)



# Faculty

Akrivos N. (Greece)

Arjona Sanchez A. (Spain)

Bakouras N. (Greece)

Bakrin N. (France)

Botsolis K. (Greece)

Christopoulou A. (Greece)

Classe J.M. (France)

Deraco M. (Italy)

Efstathiou E. (Greece)

Emmanouilides Ch. (Greece)

Fagotti A.(Italy)

Farmakis D. (Greece)

Floros Th. (Greece)

Hilaris G. (Greece)

lavazzo Ch. (Greece)

Kalles V. (Greece)

Kalogiannidis I. (Greece)

Kecmanovic D. (Serbia)

Kopanakis N. (Greece)

Kyriazanos J. (Greece)

Kyriazi St. (Greece)

Larentzakis A. (Greece)

Li Y. (China)

Lianos E. (Greece)

Lo Dico R. (France)

Metaxas Th. (Greece)

Nissan A. (Israel)

Papadimitriou Ch. (Greece)

Papakonstantinou K. (Greece)

Raptis A. (Greece)

Sammartino P. (Italy)

Sioulas V. (Greece)

Spiliotis J. (Greece)

Stamou K. (Greece)

Sugarbaker P. (USA)

Tentes A.-A. (Greece)

Topgul K. (Turkey)

Tsiatas M. (Greece)

Van Driel W. (Netherlands)

Vizza E. (Italy)



# Thursday, April 11<sup>th</sup> 2019

16:00	Registrations	
16:30 - 17:30	Oral Presentations	
17:30 - 17:50	<b>LECTURE</b> Chairmen: <b>A. Raptis, M. Tsiatas</b>	
	Imaging algorithm in PC from ovarian cancer <b>St. Kyriazi</b> (Greece)	
17:50 - 18:50	ROUND TABLE MEDICAL ONCOLOGISTS OPINION ON OVARIAN CANCER Chairmen: M. Tsiatas, A. Christopoulou	
17:50 - 18:10	The role of PARP inhibitory <b>E. Lianos</b> (Greece)	
18:10 - 18:30	The role of immunotherapy in advanced ovarian cancer <b>M. Tsiatas</b> (Greece)	
18:30 - 18:50	Genetic aspects of epithelial ovarian cancer. Clinical implications <b>Ch. Emmanouilides</b> (Greece)	
18:50 - 19:10	Coffee break	
19:10 - 19:30	<b>LECTURE</b> Chairmen: <b>Ch. lavazzo, V. Kalles</b>	
	Laparoscopy staging in advanced ovarian cancer <b>A. Fagotti</b> (Italy)	
19:30 - 19:50	LECTURE Chairmen: P. Sammartino, A. Raptis	
	How Biology and Genetics influence ovarian cancer prognosis and therapy <b>E. Vizza</b> (Italy)	



### Thursday, April 11th 2019

19:50 - 20:10 **LECTURE** 

Chairmen: K. Topgul, I. Kalogiannidis

Protocols in management of ovarian cancer

**R. Lo Dico** (France)

20:10 - 20:30 **LECTURE** 

Chairmen: N. Akrivos, V. Sioulas

Management of borderline ovarian tumors with peritoneal implants

I. Kalogiannidis (Greece)

20:30 - 20:50 **LECTURE** 

Chairmen: J. Spiliotis, P. Sammartino

PIPAC in management of peritoneal metastasis

**K. Topgul** (Turkey)

20:50 - 21:10 **LECTURE** 

Chairmen: P. Sugarbaker, Y. Li

HIPEC for ovarian cancer, an update

J. Spiliotis (Greece)

21:10 - 21:30 **Opening Ceremony** 

# Friday, April 12<sup>th</sup> 2019

08:30 - 09:30	Oral Presentations
09:30 - 09:50	LECTURE Chairmen: N. Akrivos, N. Bakouras
	Organ sparing cytoreductive surgery in ovarian cancer  J. Kyriazanos (Greece)
09:50 - 10:10	LECTURE Chairmen: J. Spiliotis, A. Arjona Sanchez
	Neoadjuvant chemotherapy approaches in advanced primary ovarian cancer. When does it make sense? <b>Ch. Papadimitriou</b> (Greece)
10:10 - 11:10	ROUND TABLE SURGICAL ONCOLOGISTS OPINION ON OVARIAN CANCER Chairmen: J. Kyriazanos, A. Larentzakis
10:10 - 10:30	Surgery for advanced ovarian cancer where and when should stop <b>K. Stamou</b> (Greece)
10:30 - 10:50	Advanced ovarian cancer surgical management <b>A. Nissan</b> (Israel)
10:50 - 11:10	Advanced ovarian cancer: urgent surgical approach  N. Kopanakis (Greece)
11:10 - 11:30	Coffee break
11:30 - 11:50	LECTURE Chairmen: N. Kopanakis, P. Sammartino
	CRS and HIPEC by minimally invasive approach in primary peritoneal carcinomatosis from ovarian cancer, a new point of view <b>A. Arjona Sanchez</b> (Spain)
11:50 - 12:10	LECTURE Chairmen: J. Kyriazanos, J. Spiliotis
	Serous Papillary Peritoneal Carcinoma (SPPC)  M. Deraco (Italy)

# Friday, April 12th 2019

12:10 - 12:30 **LECTURE** 

Chairmen: N. Kopanakis, G. Hilaris

Primary debulking surgery versus Interval debulking surgery after neo-adjuvant chemotherapy for patients with high-grade serous ovarian, fallopian tube and primary peritoneal cancer and diffuse peritoneal metastases. Outcome in selected patients in both treatment groups receiving peritonectomy procedures plus HIPEC

**P. Sammartino** (Italy)

12:30 - 14:30 Break

14:30 - 15:30 Oral Presentations

15:30 - 16:30 **SURVEY** 

15:30 - 15:45 **N. Kopanakis** (Greece)

15:45 - 16:00 **Ch. lavazzo** (Greece)

16:00 - 16:15 **M. Tsiatas** (Greece)

16:15 - 16:30 Discussion

16:30 - 16:50 | LECTURE

Chairmen: A. Christopoulou, M. Tsiatas

Chemotherapy every 3 or every 1 week as first line treatment

Th. Floros (Greece)

16:50 - 17:10 LECTURE

Chairmen: N. Bakouras, Ch. Emmanouilides

The role of targeted therapies in ovarian cancer

**A. Christopoulou** (Greece)

17:10 - 17:30 Coffee break

17:30 - 17:50 **LECTURE** 

Chairmen: J. Spiliotis, N. Bakrin

Role of HIPEC ub recurrent ovarian cancer

**J.M. Classe** (France)



# Friday, April 12th 2019

17:50 - 18:10 **LECTURE** 

Chairmen: A. Raptis, A. Christopoulou

New frontiers in the management of advanced ovarian cancer

**K. Botsolis** (Greece)

18:10 - 18:30 | LECTURE

Chairmen: J. Spiliotis, K. Topgul

Difficulties of pelvic surgery during cytoreduction for advance ovarian cancer

**D. Kecmanovic** (Serbia)

18:30 - 18:50 **LECTURE** 

Chairmen: N. Kopanakis, K. Topgul

Timing for HIPEC

J. Spiliotis (Greece)

18:50 - 19:10 **LECTURE** 

Chairmen: A.-A. Tentes, J. Spiliotis

Management of peritoneal metastases from ovarian cancer, a historical perspective

**P. Sugarbaker** (USA)



# Saturday, April 13<sup>th</sup> 2019

08:30 - 09:30	Oral Presentations	
09:30 - 10:30	ROUND TABLE GYNECOLOGICAL ONCOLOGISTS OPINION ON OVARIAN CANCER Chairmen: V. Sioulas, D. Farmakis	
09:30 - 09:50	Lymphadenectomy in ovarian cancer. A technical gimmick or true clinical value <b>N. Akrivos</b> (Greece)	
09:50 - 10:10	Risk reducing surgery for patients at hereditary risk for ovarian cancer <b>V. Sioulas</b> (Greece)	
10:10 - 10:30	Indications for HIPEC in treatment of ovarian carcinoma <b>W. Van Driel</b> (Netherlands)	
10:30 - 10:50	Coffee break	
10:50 - 11:10	LECTURE Chairmen: J.M. Classe, K. Papakonstantinou	
	Prognosis factors associated to early relapse after complete CRS and HIPEC in ovarian peritoneal carcinomatosis  N. Bakrin (France)	
11:10 - 11:30	LECTURE Chairmen: J. Kyriazanos, Th. Metaxas	
	Why are we failing to cure ovarian cancer? <b>K. Papakonstantinou</b> (Greece)	
11:30 - 11:50	LECTURE Chairmen: J. Spiliotis, M. Deraco	
	CRS+HIPEC to treat ovarian cancer: Practice changing in China <b>Y. Li</b> (China)	
11:50 - 12:10	LECTURE Chairmen: N. Kopanakis, N. Bakouras	
	HIPEC Morbidity / Mortality  E. Efstathiou (Greece)	
12:10 - 13:30	ROUND TABLE MEET THE EXPERTS	
13:30	Conclusions	

#### **General Information**

#### **Dates and Symposium Venue**

April 11<sup>th</sup> - 13<sup>th</sup> 2019 Eugenides Foundation

(387 Syggrou Ave, 175 64, Palaio Faliro, Athens, Greece, www.eugenfound.edu.gr)

#### **Registration Fees**

Category	Fee
Specialists	500€
Residents	320€
Post Graduate Students	125€
Nurses	80€
Undergraduate Students	50 €
Undergraduate Students (participation only)	Free
One day Registration	150€

<sup>\*</sup>VAT 24% is included in the above mentioned fees

#### Registration fees include:

- Admission to the Symposium
- Symposium material
- Certificate of attendance
- Admission to the exhibition

#### Official Language

English will be the official language of the Symposium and no simultaneous translation will be provided.

#### **CME Accreditation**

The Symposium will be accredited with CME by the European Accreditation Council for Continuing Medical Education (EACCME®).

#### **Certificate of Attendance**

According to the European Accreditation Council for Continuing Medical Education (EACCME®), each medical specialist should claim only those credits that he/she actually spent in the educational activity. Certificates will be provided after the completion of the Scientific Program.

#### **Symposium Badge**

Delegates are obliged to show their Symposium badge at the entrance of Symposium Halls for their attendance time to be registered.

#### **Bar Code**

A bar code system will be implemented during the Symposium, to register the general participation of all delegates.

#### **Exhibition**

Within the Symposium area there will be an exhibition of medical equipment and pharmaceutical products.

#### **Presentations**

Available visual equipment for all presentations will be through power point presentation. For power point use, your presence to the "technical reception desk" is required one hour prior to the time of your presentation in order to check the compatibility of your cd or usb stick and to copy the relevant files. Use of personal computers will not be feasible.

#### Athens Weather

Athens weather in April is packed with Mediterranean sunshine and temperatures around 20°C means you will enjoy superb conditions as you explore the ancient city.

#### **Visa Regulations for Greece**

Greece is a full European Union member and follows the Schengen Agreement provision and the subsequent EU legislation concerning short-term visas.

Visa regulations depend on your nationality and country of origin. Please contact your local Embassy/ Consulate for full and official instructions on the specific visa regulations and application procedures that apply to you. It is the responsibility of the participant to obtain a visa, if required. For further details please visit: https://www.mfa.gr/en/visas/

#### Currency

Greece's monetary unit is the Euro. No other currency is accepted and it is best to exchange dollars or other currency at a bank. The **exchange rates** are all the same throughout the country and you exchange money at a bank or official exchange shop where you will get the best running rates. Banks are open from 9:00 AM until 2:00 PM.

#### **Insurance**

We cannot accept responsibility for any personal loss, accidents or damages to participants and/or accompanying persons. Participants are strongly advised to obtain personal insurance to cover any eventuality that may occur during the Symposium.

#### The airport

The new award winning Athens International Airport, Eleftherios Venizelos, serves 83 international destinations. Its close proximity to the city center, 30 minutes by car and 40 minutes by train, makes Athens easily accessible.

#### **Symposium Secretariat**



#### www.globalevents.gr

#### THESSALONIKI OFFICE

50A Stadiou Street 55534 Thessaloniki, Greece

+302310 247743

+302310 247746

info@globalevents.gr

#### ATHENS OFFICE

2, Valestra str. & 168, Syngrou Av., 17671, Kallithea, Athens, Greece

+30 210 3250260

+30 2310 247746

athens@globalevents.gr



# YOUR PARTNER IN REGIONAL CANCER THERAPIES

HIPEC Hyperthermic Intra-Peritoneal Chemotherapy

ORANDIO

HITHOC Hyperthermic Intra Thoracic Chemotherapy

ILP Isolated Limb Perfusion

ILIP Isolated Liver Perfusion

ILUP Isolated Lung Perfusion



MARKET LEADER

25.000

TREATED PATIENTS

20

YEARS' EXPERIENCE



RAND ACADEMY